Actikerall 5 mg/100 mg/g uz ādas lietojams šķīdums Letland - Letlands - Zāļu valsts aģentūra

actikerall 5 mg/100 mg/g uz ādas lietojams šķīdums

almirall hermal gmbh, germany - fluorouracilum, skābes salicylicum - uz ādas lietojams šķīdums - 5 mg/100 mg/g

Lonsurf Europese Unie - Letlands - EMA (European Medicines Agency)

lonsurf

les laboratoires servier - trifluridine, tipiracil hidrohlorīds - kolorektālie jaunveidojumi - antineoplastiski līdzekļi - colorectal cancerlonsurf is indicated in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (crc) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and/or anti-egfr agents. lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (crc) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti egfr agentsgastric cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.

Teysuno Europese Unie - Letlands - EMA (European Medicines Agency)

teysuno

nordic group b.v. - ftorafūrs, gimeracil, oteracil - kuņģa-zarnu trakta traucējumi - antineoplastiski līdzekļi - teysuno is indicated in adults:- for the treatment of advanced gastric cancer when given in combination with cisplatin (see section 5. - as monotherapy or in combination with oxaliplatin or irinotecan, with or without bevacizumab, for the treatment of patients with metastatic colorectal cancer for whom it is not possible to continue treatment with another fluoropyrimidine due to hand-foot syndrome or cardiovascular toxicity that developed in the adjuvant or metastatic setting.

Inaqovi Europese Unie - Letlands - EMA (European Medicines Agency)

inaqovi

otsuka pharmaceutical netherlands b.v. - cedazuridine, decitabine - leikēmija, mieloīds - antineoplastiski līdzekļi - inaqovi is indicated as monotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for standard induction chemotherapy.